Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPARα mice

Molecular Biology Reports

Volumn 40, Issue 3, 2013, Pages 2449-2459

  Chen, Wei ^a   Chen, Wenjie ^a   Xia, Yanping ^a   Zhao, Xuelan ^a   Wang, Hao ^a   Yu, Maohua ^a   Li, Yiming ^a   Ye, Hongying ^a   Zhang, Yu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cardiomyopathy; Diabetes mellitus; Fatty acids; Lipid metabolism; PPAR

Indexed keywords

ASTRAGALUS POLYSACCHARIDE; FATTY ACID; GLUCOSE; MYOSIN HEAVY CHAIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYSACCHARIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTRAGALUS MEMBRANACEUS; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; GENE; GENE ACTIVATION; GENE REPRESSION; GENE TARGETING; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HEART DISEASE; HEART MUSCLE; HEART MUSCLE CELL; LIPID DIET; LIPID STORAGE; LIPOTOXICITY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PPAR ALPHA GENE; REGULATORY MECHANISM;

ANIMALS; ASTRAGALUS PLANT; CARDIOMYOPATHIES; DIET, HIGH-FAT; ENERGY METABOLISM; GENE EXPRESSION REGULATION; HEMODYNAMICS; LIPID METABOLISM; MALE; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; MYOSIN HEAVY CHAINS; POLYSACCHARIDES; PPAR ALPHA; SIGNAL TRANSDUCTION;

MUS;

EID: 84878422065     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2325-1     Document Type: Article

References (34)

1. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595-602
2. Gamble J, Lopaschuk GD (1994) Glycolysis and glucose oxidation during reperfusion of ischemic hearts from diabetic rats. Biochim Biophys Acta 1225:191-199
3. Schaffer JE (2003) Lipotoxicity: when tissues overeat. Curr Opin Lipidol 4:281-287
4. Sunni S, Bishop SP, Kent SP (2001) Diabetic cardiomyopathy, a morphological study of intramyocardial arteries. Arch Pathol Lab Med 110(5):375-3895
5. Huss JM, Kelly DP (2004) Nuclear receptor signaling and cardiac energetics. Circ Res 95:568-578
6. Finck B, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP (2002) The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109:121-130
7. Finck B, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP (2003) A critical role for PPARα- mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation of phenotype by dietary fat content. Proc. Natl. Acad. Sci. U S A. 100:1226-1231
8. Zou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unqer RH (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97:1784-1789
9. Ni Y, Su Q, Liu X (1998) Experimental study of optimized techniques of water decoction extraction of Astragalus polysaccharide. China J. Chin. Med. 23(6):284-286
10. Chen W, Li Y, Yu M (2008) Astragalus Polysaccharides: an Effective Treatment for Diabetes Prevention in NOD Mice. Exp Clin Endocrinol Diabetes 116(8):468-474
11. Chen W, Li Y, Yu M (2010) Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation. J. Diabetes Complica. 24(3):199-208
12. Rogers JH, Tamirisa P, Kovacs A, Weinheimer C, Courtois M, Blumer KJ, Kelly DP, Muslin AJ (1999) RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J Clin Invest. 104:567-576
13. Okumura K, Hayashi K, Morishima I, Murase K, Matsui H, Toki Y, Ito T (1998) Simultaneous quantitation of ceramides and 1,2-diacylglycerol in tissues by Iatroscan thin-layer chromatography- flame- osnization detection. Lipids 33:529-532
14. Saburi Y, Okumura K, Matsui H, Hayashi K, Kamiya H, Takahashi R, Matsubara K, Ito M (2003) Changes in distinct species of 1,2-diacylglycerol in cardiac hypertrophy due to energy metabolic disorder. Cardiovasc Res 57:92-100
15. Belke DD, Lasen TS, Lopaschuk GD, Severson DL (1999) Glucose and fatty acid metabolism in the isolated working mouse heart. Am J Physiol 277:R1210-R1217
16. Chen W, Yu MH, Li YM, Chen WJ, Xia YP (2010) Beneficial effects of astragalus polysaccharides treatment on cardiac chymase activities and cardiomyopathy in diabetic hamsters. Acta Diabetol 47(Suppl 1):S35-S46
17. Proornima IG, Parikh P, Shannon RP (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98:596-605
18. Schaffer JE, Lodish HF (1994) Expression cloning and characterization of a novel adipocyte long- chain fatty acid transport protein. Cell 79:427-436
19. Desvergne B, Michalik L, Wahli W (2006) Transcriptional regulation of metabolism. Physiol Rev 86:465-514
20. Brown JD, Plutzky J (2007) Peroxisome porliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115:518-533
21. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362(17):1563-1574
22. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diatetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861
23. Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J (2004) The peroxisome proliferator- activated receptor alpha agonist ciprofibrate inhibits apolipoprotien B mRNA editing in low density lipoprotein receptor- deficient mice. J Biol Chem 279:28662-28669
24. Tordjman K, Bernal-Mizrachi C, Zemany L, Weng S, Feng C, Zhang F, Leone TC, Coleman T, Kelly DP, Semenkovich CF (2001) PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107:1025-1034
25. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD (2006) Chronic activation of PPARalpha is detrimental to cardiac revovery after ischemia. Am. J. Physiol. Heart Circ. Physiol. 290:H87-H95
26. Young ME, Laws FA, Goodwin GW, Taegtmeyer H (2001) Reactivation of peroxisome proliferator- actated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276:44390-44395
27. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H (2004) Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB. J. 18:1692-1700
28. Belke DD, Larsen TS, Gibbs EM, Severson DL (2000) Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am. J. Physiol. Endocrinol. Metab. 279:E1104-E1113
29. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Haito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T (2000) Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with age-dependent cardiac toxicity. J Biol Chem 275:22293-22299
30. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP, Lopaschuk GD (2002) A role for peroxisome proliferator-activated receptor alpha in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 277:4098-4103
31. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP (2007) Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1 alpha gene regulatory pathway. Circulation 115:909-917
32. Yang J, Sambandam N, Ham X, Gross RW, Courtosis M, Kovacs A, Febbraio M, Finck BN, Kelly DP (2007) CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 100:1208-1217
33. Boudina S, Sena S, O'Neill BT, Tathireddy P, Young ME, Abel ED (2005) Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112:2686-2695
34. Depre C, Young ME, Ying J, Ahuja HS, Han Q, Garza N, Davies PJ, Taegtmeyer H (2000) Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 32:985-996